Brian Armstrong, the chief executive officer of cryptocurrency exchange Coinbase Global Inc. (NASDAQ: COIN), disclosed on Monday that his biotechnology startup, NewLimit, is engaged in developing strategies aimed at extending the human lifespan by addressing diseases commonly associated with aging. Founded in 2021, NewLimit's long-term objective revolves around enhancing "healthspan"—the period during which individuals maintain robust health—by restoring cells to a more youthful and functional state.
In a statement made via X (formerly Twitter), Armstrong shared insights into NewLimit’s mission, conveying enthusiasm about the company's approach to aging and disease. Highlighting that many significant illnesses correlate with the natural aging process, Armstrong believes that reprogramming or rejuvenating cellular function to emulate their younger state could essentially prevent or eliminate the onset of these age-related diseases.
Armstrong’s remarks were accompanied by a clip from a recent podcast featuring Rick Robin, which further elaborated on the scientific rationale behind targeting the cellular mechanisms implicated in aging. By reversing cellular aging or restoring youthful cellular activity, NewLimit seeks to address a broad spectrum of health conditions typically emerging later in life, potentially disrupting traditional paradigms of disease management.
NewLimit’s financial progression reflects strong investor interest in this emerging field. In October, the company successfully raised $45 million in capital, a round that followed only five months after its Series B funding completion. This infusion valued the startup at $1.62 billion, establishing it as a robust player within the longevity biotech arena. The leadership at NewLimit anticipates this capital will support the initiation of clinical studies within the coming years, marking a critical phase in translating their scientific hypotheses into therapeutics.
The pursuit of human lifespan extension has gained notable momentum in recent years, with multiple enterprises striving to unlock biological mechanisms that lead to aging and associated diseases. High-profile investments have surfaced, such as that from Sam Altman, CEO of OpenAI, who committed $180 million to Retro Biosciences, a company focused on scalable, cost-effective approaches to combat aging. Retro Biosciences reportedly seeks to achieve a valuation of $5 billion, underscoring the significant capital inflows directed at longevity research.
Despite this bullish interest, longevity-focused publicly traded companies have experienced substantial stock price contractions in 2025. Data recorded at 1:00 a.m. ET highlights the challenging market environment these firms currently face, including:
- Klotho Neurosciences Inc. (NASDAQ: KLTO), which declined by 40.48% to $0.32 per share
- Telomir Pharmaceuticals Inc. (NASDAQ: TELO), whose stock price dropped 64.78% to $1.49
- Longevity Health Holdings Inc. (OTCQB: XAGE), which suffered a notable 97.96% decrease, trading at $0.30
This market contraction reflects the inherent uncertainties and risks associated with investing in early-stage biotechnology firms focused on complex biological challenges such as aging.
Platforms like Benzinga Edge provide real-time stock alerts and trading tools that assist investors in navigating volatile sectors like longevity biotech. Such analytics are especially pertinent given the pronounced recent market movements experienced by firms such as KLTO and TELO.